Autologous AML Platform
A Champions Research Platform
Champions' innovative new platform enables Acute Myeloid Leukemia (AML) researchers the ability to better understand their therapeutic mechanism of action.
The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology drugs in only 4 days using primary patient specimens.
Download the Platform Sheet